653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma

925

Conclusion cited from the abstract: 

This first analysis of pts treated with VenDd +/- V demonstrate a tolerable safety profile with encouraging efficacy, notably among t(11;14) pts treated with VenDd who had an ORR of 92%. No new safety signals were observed. Although the study is currently on partial clinical hold, enrolled pts continue to be followed. Analysis will be updated at presentation.

Double-click:

926

Conclusion cited from the abstract: In both phases of this study, Ven+d was efficacious and demonstrated tolerable safety in pts with t(11;14) R/R MM. These results support further investigation of Ven combinations in this pt population. This combination is also being investigated in the ongoing Phase 3 trial M13-494 (CANOVA) in t(11;14) positive R/R MM.

Double-click:
   

Conclusion cited from the abstract: The adverse events observed to date were manageable and consistent with known toxicities of CAR T therapies. Initial efficacy results with bb21217 CAR T therapy in heavily pretreated RRMM are encouraging, with 83% of patients demonstrating clinical response. Emerging data demonstrate long-term persistence of CAR T cells in long-term responders. Updated data to be presented will help determine whether treatment with bb21217 results in sustained CAR T cell persistence and durable clinical responses, and whether bb21217 is tolerated at higher doses.  

 

Conclusion cited from the abstract: Findings from the ongoing CARTITUDE-1 trial suggest that JNJ-4528 is a differentiated CAR-T cell therapy that is highly active at a relatively low dose, potentially related to a preferential and consistent in vivo expansion of CD8+ CAR+ T cells displaying a central memory phenotype.   

 

Conclusion cited from the abstract: 

KRD-D quadruple regimen was safe and well tolerated, and provided an effective salvage in a cohort of induction resistant MM Pts, with an ORR of 91%, with deep responses achieved in 71%, equivalent to 2nd line triplet regimens in non-selected MM. Single cell analysis showed a dramatic change in the PC transcriptome following therapy. Furthermore, differences in gene expression patterns between responders and non-responders unveil potentially druggable escape mechanisms used by the highly resistant tumors including immune checkpoints that may serve as perspective biomarkers and therapeutic targets.

Double-click:

930

Conclusion cited from the abstract: 

Our study demonstrates an improved efficacy with the bivalent BM38 CAR-T therapy for RRMM with a high ORR, especially a higher rate and a longer duration of sCR and effective elimination for extramedullary lesions. No neurotoxicity was observed. CRS and other toxicities were manageable. These initial data provide strong evidence to support the further development of the dual-target CAR-T therapy for RRMM.

Clinical trial information: ChiCTR1800018143

Double-click: